Media coverage
6
Media coverage
Title Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet Nasdaq Country/Territory United States Date 3/07/19 URL https://www.nasdaq.com/press-release/karyopharm-announces-fda-approval-of-xpovio-selinexor-for-the-treatment-of-patients-with-relapsed-20190703-00479 Persons Sundar Jagannath Title Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet SPi World News Country/Territory United Kingdom Date 3/07/19 URL https://www.sectorpublishingintelligence.co.uk/news/2378534/karyopharm-announces-fda-approval-of-xpovio-selinexor-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma Persons Sundar Jagannath Title KARYOPHARM THERAPEUTICS : Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet MarketScreener.com Country/Territory United States Date 3/07/19 URL https://www.marketscreener.com/KARYOPHARM-THERAPEUTICS-I-14825950/news/Karyopharm-Therapeutics-Announces-FDA-Approval-of-XPOVIO-trade-selinexor-for-the-Treatment-of-P-28849727/ Persons Sundar Jagannath Title Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet Crwe World Country/Territory United States Date 3/07/19 URL crweworld.com/article/news-provided-by-globenewswire/1153930/karyopharm-announces-fda-approval-of-xpovio-selinexor-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma Persons Sundar Jagannath Title Karyopharm Announces FDA Approval of XPOVIO ™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet Stockwatch Country/Territory Canada Date 3/07/19 URL www.stockwatch.com/News/Item.aspx?bid=U-z7674624-U%3aKPTI-20190703&symbol=KPTI®ion=U Persons Sundar Jagannath Title Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet GlobeNewswire Country/Territory United States Date 3/07/19 URL https://www.globenewswire.com/news-release/2019/07/03/1878060/0/en/Karyopharm-Announces-FDA-Approval-of-XPOVIO-selinexor-for-the-Treatment-of-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma.html Persons Sundar Jagannath